Certara IQ™ Global Roadshow
Certara IQ™ is going on the road. From APAC to Europe to North America, our…
CertaraFebruary 12, 2026
Anti-PD-(L)1 Antibodies: Insights From QSP-Based Meta-Analysis
Anti-PD-1 and anti-PD-L1 antibodies have transformed cancer immunotherapy, yet clinical meta-analyses suggest differences in efficacy…
CertaraFebruary 11, 2026
AI in Alzheimer’s drug development: Where do disease-modifying interventions go from here?
Explore how AI-enabled QSP and model-informed drug development are reshaping Alzheimer’s disease-modifying therapies, from amyloid…
CertaraFebruary 2, 2026
First-in-human dosing model for MDX2004, a novel trispecific CD3xCD28/4-1BB antibody-fusion protein for advanced malignancies
Learn how QSP modeling enabled safe, data-driven FIH dose prediction for the trispecific T-cell activator…
CertaraDecember 16, 2025
QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™
Japan: February 26, 2026 - 1:00 - 5:00 pm | Korea: Wednesday, March 4, 2026…
CertaraDecember 9, 2025
Quantitative Systems Pharmacology Modeling to Support the Preclinical Development of Radiopharmaceuticals
Quantitative Systems Pharmacology (QSP) modeling tackles preclinical radiopharmaceuticals development challenges, from design to dose optimization.
CertaraNovember 14, 2025
ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™
At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…
CertaraNovember 13, 2025
De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development
Learn how Early Feasibility Assessment and QSP modeling improve drug design, de-risk feasibility studies, &…
CertaraNovember 7, 2025
